In this review, we discuss the crosstalk between oncogenic KRAS, inflammation and immune-modulatory mechanisms in cancer, with a focus on KRAS-induced NLRP3 inflammasome activation and programmed death-ligand-1 (PD-L1) expression. The gene discussed is NLRP3; the disease is cancer.